P2X Purinoceptor 7 (P2Z Receptor or P2RX7) – Pipeline Review, H2 2016

Global Markets Direct’s, ‘P2X Purinoceptor 7 (P2Z Receptor or P2RX7) – Pipeline Review, H2 2016’, provides in depth analysis on P2X Purinoceptor 7 (P2Z Receptor or P2RX7) targeted pipeline therapeutics.

The report provides comprehensive information on the P2X Purinoceptor 7 (P2Z Receptor or P2RX7) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in P2X Purinoceptor 7 (P2Z Receptor or P2RX7) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

Certain sections in the report may be removed or altered based on the availability and relevance of data.

Updated report will be delivered in 48 hours of order confirmation.

Scope

The report provides a snapshot of the global therapeutic landscape for P2X Purinoceptor 7 (P2Z Receptor or P2RX7)

The report reviews P2X Purinoceptor 7 (P2Z Receptor or P2RX7) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in P2X Purinoceptor 7 (P2Z Receptor or P2RX7) targeted therapeutics and enlists all their major and minor projects

The report assesses P2X Purinoceptor 7 (P2Z Receptor or P2RX7) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to P2X Purinoceptor 7 (P2Z Receptor or P2RX7) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for P2X Purinoceptor 7 (P2Z Receptor or P2RX7)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding P2X Purinoceptor 7 (P2Z Receptor or P2RX7) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Affectis Pharmaceuticals AG

Axxam SpA

Biosceptre (Aust) Pty Ltd

Evotec AG

Johnson & Johnson

Medestea Research & Production SpA

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

P2X Purinoceptor 7 (P2Z Receptor or P2RX7) Overview 6

Therapeutics Development 7

P2X Purinoceptor 7 (P2Z Receptor or P2RX7) - Products under Development by Stage of Development 7

P2X Purinoceptor 7 (P2Z Receptor or P2RX7) - Products under Development by Therapy Area 8

P2X Purinoceptor 7 (P2Z Receptor or P2RX7) - Products under Development by Indication 9

P2X Purinoceptor 7 (P2Z Receptor or P2RX7) - Pipeline Products Glance 10

Late Stage Products 10

Early Stage Products 11

Unknown Stage Products 12

P2X Purinoceptor 7 (P2Z Receptor or P2RX7) - Products under Development by Companies 13

P2X Purinoceptor 7 (P2Z Receptor or P2RX7) - Therapeutics Assessment 16

Assessment by Monotherapy/Combination Products 16

Assessment by Mechanism of Action 17

Assessment by Route of Administration 18

Assessment by Molecule Type 20

P2X Purinoceptor 7 (P2Z Receptor or P2RX7) - Companies Involved in Therapeutics Development 22

Affectis Pharmaceuticals AG 22

Axxam SpA 23

Biosceptre (Aust) Pty Ltd 24

Evotec AG 25

Johnson & Johnson 26

Medestea Research & Production SpA 27

P2X Purinoceptor 7 (P2Z Receptor or P2RX7) - Drug Profiles 28

AFC-5128 - Drug Profile 28

Product Description 28

Mechanism Of Action 28

R&D Progress 28

BIL-010t - Drug Profile 29

Product Description 29

Mechanism Of Action 29

R&D Progress 29

BIL-06v - Drug Profile 30

Product Description 30

Mechanism Of Action 30

R&D Progress 30

BIL-07v - Drug Profile 31

Product Description 31

Mechanism Of Action 31

R&D Progress 31

EVT-401 - Drug Profile 32

Product Description 32

Mechanism Of Action 32

R&D Progress 32

JNJ-47965567 - Drug Profile 33

Product Description 33

Mechanism Of Action 33

R&D Progress 33

MED-1101 - Drug Profile 34

Product Description 34

Mechanism Of Action 34

R&D Progress 34

Small Molecule to Antagonize P2X7 Receptor for Central Nervous System - Drug Profile 35

Product Description 35

Mechanism Of Action 35

R&D Progress 35

Small Molecules to Antagonize P2RX7 for CNS Disorders, Autoimmune Disorders and Inflammation - Drug Profile 36

Product Description 36

Mechanism Of Action 36

R&D Progress 36

P2X Purinoceptor 7 (P2Z Receptor or P2RX7) - Dormant Projects 37

P2X Purinoceptor 7 (P2Z Receptor or P2RX7) - Discontinued Products 38

P2X Purinoceptor 7 (P2Z Receptor or P2RX7) - Featured News & Press Releases 39

Dec 18, 2014: Alzheimer’s Drug Discovery Foundation And Axxam Continue Their Successful Collaboration To Develop Novel Therapeutics For Alzheimer’s Disease 39

Jul 22, 2014: Biosceptre Announces Positive Phase I Results for BIL-010t to Treat Basal Cell Carcinoma 39

Jan 25, 2012: Affectis Receives European Patent For AFC-5128 And Other P2X7 Antagonists 40

Jun 29, 2009: Evotec Announces The Successful Completion Of The First Phase I Study With EVT 401 40

Oct 09, 2008: Evotec Announces Phase I Initiation With P2X7 Antagonist 41

Appendix 42

Methodology 42

Coverage 42

Secondary Research 42

Primary Research 42

Expert Panel Validation 42

Contact Us 42

Disclaimer 43

List of Tables

List of Tables

Number of Products under Development for, H2 2016 7

Number of Products under Development by Therapy Area, H2 2016 8

Number of Products under Development by Indication, H2 2016 9

Comparative Analysis by Late Stage Development, H2 2016 10

Comparative Analysis by Early Stage Products, H2 2016 11

Comparative Analysis by Unknown Stage Development, H2 2016 12

Number of Products under Development by Companies, H2 2016 13

Products under Development by Companies, H2 2016 14

Products under Development by Companies, H2 2016 (Contd..1) 15

Assessment by Monotherapy/Combination Products, H2 2016 16

Number of Products by Stage and Mechanism of Action, H2 2016 17

Number of Products by Stage and Route of Administration, H2 2016 19

Number of Products by Stage and Molecule Type, H2 2016 21

Pipeline by Affectis Pharmaceuticals AG, H2 2016 22

Pipeline by Axxam SpA, H2 2016 23

Pipeline by Biosceptre (Aust) Pty Ltd, H2 2016 24

Pipeline by Evotec AG, H2 2016 25

Pipeline by Johnson & Johnson, H2 2016 26

Pipeline by Medestea Research & Production SpA, H2 2016 27

Dormant Projects, H2 2016 37

Discontinued Products, H2 2016 38

List of Figures

List of Figures

Number of Products under Development for, H2 2016 7

Number of Products under Development by Therapy Area, H2 2016 8

Number of Products under Development by Top 10 Indication, H2 2016 9

Comparative Analysis by Early Stage Products, H2 2016 11

Assessment by Monotherapy/Combination Products, H2 2016 16

Number of Products by Stage and Mechanism of Actions, H2 2016 17

Number of Products by Routes of Administration, H2 2016 18

Number of Products by Stage and Routes of Administration, H2 2016 18

Number of Products by Molecule Types, H2 2016 20

Number of Products by Stage and Molecule Type, H2 2016 20

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports